GlassScriptPhysician profile
Leeanne Ardoin
NPI 1003346768
$5,702.85
in general payments reported to CMS, 2019-2025
42 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,026 · 2022: $1,277 · 2023: $1,314 · 2024: $1,064 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.70 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $473.49 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $444.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $384.39 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $321.64 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $301.66 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $292.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.34 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $271.51 | 2021-2025 | Rexulti |
| Pfizer INC. | $217.26 | 2021-2025 | |
| Axsome Therapeutics, INC. | $199.78 | 2023-2025 | Auvelity |
| Amgen INC. | $199.38 | 2021-2025 | Otezla, Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $162.03 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.01 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $102.10 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leeanne Ardoin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.